{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:36:49Z","timestamp":1789508209316,"version":"build-2803163510"},"reference-count":207,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.idc.2009.06.013","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T05:35:33Z","timestamp":1258004133000},"page":"997-1026","source":"Crossref","is-referenced-by-count":65,"title":["Macrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline"],"prefix":"10.1016","volume":"23","author":[{"given":"Jerry M.","family":"Zuckerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fozia","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartholomew R.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/jm00394a001","article-title":"Macrolides with gastrointestinal motor stimulating activity","volume":"30","author":"Omura","year":"1987","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib2","first-page":"137","article-title":"Clarithromycin and azithromycin: new macrolide antibiotics","volume":"11","author":"Piscitelli","year":"1992","journal-title":"Clin Pharm"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1A038","article-title":"Telithromycin: the first of the ketolides","volume":"36","author":"Shain","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"Suppl T1","key":"10.1016\/j.idc.2009.06.013_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/48.suppl_2.1","article-title":"Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site","volume":"48","author":"Douthwaite","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/PL00006814","article-title":"Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells","volume":"38","author":"Champney","year":"1999","journal-title":"Curr Microbiol"},{"issue":"18","key":"10.1016\/j.idc.2009.06.013_bib6","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2165\/00003495-200565180-00008","article-title":"Tigecycline","volume":"65","author":"Frampton","year":"2005","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1177\/106002809202600912","article-title":"Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles","volume":"26","author":"Sturgill","year":"1992","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"issue":"10","key":"10.1016\/j.idc.2009.06.013_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1128\/AAC.41.10.2251","article-title":"mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae","volume":"41","author":"Tait-Kamradt","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.013_bib10","unstructured":"Ketek (telithromycin): briefing document for the FDA Anti-Infective Drug Products Advisory Committee Meeting, January 8, 2003. Gaithersburg, MD."},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLS(B) resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3201\/eid1106.041247","article-title":"Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999\u20132003","volume":"11","author":"Malhotra-Kumar","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib13","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1128\/AAC.00057-06","article-title":"Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe","volume":"50","author":"Al-Lahham","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/AAC.01074-07","article-title":"Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation","volume":"52","author":"Wolter","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib15","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib16","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.48.6.2179-2184.2004","article-title":"Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936)","volume":"48","author":"Hirata","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib18","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/AAC.01198-06","article-title":"Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii","volume":"51","author":"Peleg","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2009.06.013_bib19","unstructured":"Abbott Laboratories. Biaxin (Clarithromycin): prescribing information. 2008;2008(12\/23)."},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0149-2918(01)80060-6","article-title":"Pharmacokinetics and tolerability of extended-release clarithromycin","volume":"23","author":"Guay","year":"2001","journal-title":"Clin Ther"},{"issue":"Suppl C","key":"10.1016\/j.idc.2009.06.013_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/37.suppl_C.37","article-title":"The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension","volume":"37","author":"Foulds","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-200746030-00005","article-title":"Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin","volume":"46","author":"Chandra","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000066766","article-title":"Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers","volume":"48","author":"Perret","year":"2002","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/0036554021000026958","article-title":"Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin","volume":"34","author":"Bhargava","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)08537-X","article-title":"Metabolism and disposition of clarithromycin in man","volume":"18","author":"Ferrero","year":"1990","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.00852-06","article-title":"Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib28","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.49.4.1656-1659.2005","article-title":"Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2009.06.013_bib30","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"10.1016\/j.idc.2009.06.013_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.idc.2009.06.013_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jac\/27.suppl_A.61","article-title":"The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans","volume":"27","author":"Fraschini","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib34","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.45.11.3104-3108.2001","article-title":"Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)","volume":"45","author":"Muller-Serieys","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib38","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.49.4.1629-1632.2005","article-title":"Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations","volume":"49","author":"Sun","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0732-8893(92)90055-X","article-title":"Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview","volume":"15","author":"Hardy","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/j.1552-4604.1993.tb04692.x","article-title":"Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics","volume":"33","author":"Chu","year":"1993","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.idc.2009.06.013_bib41","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1177\/106002809202601014","article-title":"Azithromycin: the first azalide antibiotic","volume":"26","author":"Ballow","year":"1992","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide -induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl E","key":"10.1016\/j.idc.2009.06.013_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31","author":"Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200161040-00003","article-title":"Review of macrolides and ketolides: focus on respiratory tract infections","volume":"61","author":"Zhanel","year":"2001","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0924-8579(03)00128-6","article-title":"Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment","volume":"22","author":"Cantalloube","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib46","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.idc.2009.06.013_bib47","unstructured":"Tygacil (tigecycline) prescribing information. 2008;2008(11\/28)."},{"key":"10.1016\/j.idc.2009.06.013_bib48","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/646545","article-title":"Azithromycin and clarithromycin: overview and comparison with erythromycin","volume":"13","author":"Whitman","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib50","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1128\/AAC.47.6.1963-1967.2003","article-title":"In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib51","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1128\/AAC.45.11.3242-3245.2001","volume":"45","author":"Nagai","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/AAC.46.3.783-786.2002","article-title":"Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci","volume":"46","author":"Shortridge","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib53","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib54","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.42.4.945","article-title":"Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10156-003-0258-2","article-title":"In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance","volume":"9","author":"Ubukata","year":"2003","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib56","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000, including a comparison of resistance rates since 1994\u20131995","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4065\/78.9.1113","article-title":"Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting","volume":"78","author":"Clark","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib58","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1128\/AAC.34.7.1407","article-title":"Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans","volume":"34","author":"Hardy","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2009.06.013_bib59","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.42.8.2138","article-title":"In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib60","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1128\/AAC.30.6.865","article-title":"In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide","volume":"30","author":"Fernandes","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00003495-199244010-00009","article-title":"Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential","volume":"44","author":"Peters","year":"1992","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib62","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2165\/00003495-199244050-00007","article-title":"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy","volume":"44","author":"Peters","year":"1992","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib63","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1345\/aph.1H543","article-title":"Tigecycline: a novel broad-spectrum antimicrobial","volume":"41","author":"Slover","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.01114-07","article-title":"Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program","volume":"52","author":"Castanheira","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.diagmicrobio.2006.10.013","article-title":"Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial","volume":"57","author":"Hoban","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.diagmicrobio.2008.04.012","article-title":"Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005\/2006","volume":"62","author":"Zhanel","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.diagmicrobio.2007.10.017","article-title":"Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers","volume":"60","author":"Gales","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/49.2.337","article-title":"Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study","volume":"49","author":"Portier","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1469-0691.2004.00908.x","article-title":"Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis","volume":"10","author":"Norrby","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0149-2918(03)80087-5","article-title":"Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis\/pharyngitis: a multicenter, randomized, double-blind, parallel-group study","volume":"25","author":"Quinn","year":"2003","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib74","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1097\/00006454-199312003-00006","article-title":"Comparative safety and efficacy of clarithromycin and amoxicillin\/clavulanate in the treatment of acute otitis media in children","volume":"12","author":"McCarty","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib75","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.clinthera.2005.06.012","article-title":"A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study","volume":"27","author":"Block","year":"2005","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/48.5.677","article-title":"Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections","volume":"48","author":"Ioannidis","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.inf.0000164794.50281.1a","article-title":"Large dosage amoxicillin\/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children","volume":"24","author":"Hoberman","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000151024.11703.4a","article-title":"A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media","volume":"24","author":"Arguedas","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib79","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/j.1875-9114.1998.tb03145.x","article-title":"A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis","volume":"18","author":"Adelglass","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib80","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/000348949910800408","article-title":"Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis: Sinusitis Infection Study Group","volume":"108","author":"Clifford","year":"1999","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib81","first-page":"173","article-title":"Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis","volume":"36","author":"Stefansson","year":"1998","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079904X18009","article-title":"Once daily clarithromycin extended-release vs twice-daily amoxicillin\/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study","volume":"21","author":"Riffer","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.otohns.2005.04.020","article-title":"Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults","volume":"133","author":"Murray","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib84","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/AAC.47.9.2770-2774.2003","article-title":"Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis","volume":"47","author":"Henry","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1185\/03007990802133914","article-title":"Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis","volume":"24","author":"Desrosiers","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jinf.2004.05.014","article-title":"Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis","volume":"50","author":"Roos","year":"2005","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.otohns.2004.05.010","article-title":"Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis","volume":"131","author":"Ferguson","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib88","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00003495-199753060-00006","article-title":"Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients","volume":"53","author":"Langtry","year":"1997","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib89","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0149-2918(02)80100-X","volume":"24","author":"Weiss","year":"2002","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib90","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0149-2918(00)83040-4","article-title":"Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis","volume":"22","author":"Adler","year":"2000","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02850246","article-title":"A comparative study of clarithromycin modified release and amoxicillin\/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis","volume":"18","author":"Martinot","year":"2001","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib92","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0149-2918(01)80031-X","article-title":"Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin\/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis","volume":"23","author":"Anzueto","year":"2001","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1185\/030079906X162827","article-title":"Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis","volume":"23","author":"Gotfried","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib94","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0149-2918(02)80045-5","article-title":"Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis","volume":"24","author":"Weiss","year":"2002","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib95","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0149-2918(02)85139-6","article-title":"A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes","volume":"24","author":"Wilson","year":"2002","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib96","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib97","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0149-2918(02)85136-0","article-title":"A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia","volume":"24","author":"Sokol","year":"2002","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib99","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1469-0691.2004.00906.x","article-title":"A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia","volume":"10","author":"Lode","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.idc.2009.06.013_bib100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/BF01975846","article-title":"Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia","volume":"10","author":"Kinasewitz","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/joc.2008.20.1.77","article-title":"Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875\/125 mg twice daily for 7 days","volume":"20","author":"Paris","year":"2008","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib102","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1378\/chest.128.4.2230","article-title":"Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults","volume":"128","author":"Drehobl","year":"2005","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.idc.2009.06.013_bib103","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D'Ignazio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib104","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/48.5.691","article-title":"Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections","volume":"48","author":"Contopoulos-Ioannidis","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001954.pub3","article-title":"Azithromycin for acute lower respiratory tract infections","author":"Panpanich","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00151829-200504010-00004","article-title":"Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study","volume":"4","author":"Swanson","year":"2005","journal-title":"Treat Respir Med"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib107","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1378\/chest.123.3.772","article-title":"Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis","volume":"123","author":"Amsden","year":"2003","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2006.08.043","article-title":"Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis","volume":"29","author":"Zervos","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib109","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/rmed.2003.1492","article-title":"Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis","volume":"97","author":"Hagberg","year":"2003","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib112","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib113","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000086576","article-title":"Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and\/or erythromycin","volume":"51","author":"van Rensburg","year":"2005","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.rmed.2005.11.007","article-title":"Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia","volume":"100","author":"Carbon","year":"2006","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib115","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1378\/chest.128.4.1980","article-title":"Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization","volume":"128","author":"Fogarty","year":"2005","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib116","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib117","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s15010-003-3142-1","article-title":"A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults","volume":"31","author":"Carbon","year":"2003","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib118","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial","volume":"160","author":"Vergis","year":"2000","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib119","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1128\/AAC.44.7.1796-1802.2000","article-title":"Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia: the Azithromycin Intravenous Clinical Trials Group","volume":"44","author":"Plouffe","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"10.1016\/j.idc.2009.06.013_bib120","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.163.14.1718","article-title":"Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31\/2-year experience from a veterans affairs hospital","volume":"163","author":"Feldman","year":"2003","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","article-title":"Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia","volume":"3","author":"Zervos","year":"2004","journal-title":"Treat Respir Med"},{"issue":"8","key":"10.1016\/j.idc.2009.06.013_bib122","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0149-2918(03)80132-7","volume":"25","author":"Correa","year":"2003","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.idc.2009.06.013_bib124","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1155\/2004\/461392","article-title":"Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults","volume":"11","author":"Weiss","year":"2004","journal-title":"Can Respir J"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10096-005-1295-9","article-title":"Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone","volume":"24","author":"Garcia Vazquez","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Martinez","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib127","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/379329","article-title":"Azithromycin in the treatment of Legionella pneumonia requiring hospitalization","volume":"37","author":"Plouffe","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3 Suppl 1","key":"10.1016\/j.idc.2009.06.013_bib128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3810\/pgm.2008.09.suppl52.279","article-title":"Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001\u20132005","volume":"120","author":"Sahm","year":"2008","journal-title":"Postgrad Med"},{"key":"10.1016\/j.idc.2009.06.013_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-7-1","article-title":"Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1\u20134","volume":"7","author":"Jenkins","year":"2008","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib130","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1128\/AAC.00971-07","article-title":"National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005\u20132006 U.S. Faropenem surveillance study","volume":"51","author":"Critchley","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib131","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/JCM.01653-06","article-title":"Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study","volume":"45","author":"Farrell","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"3 Suppl 1","key":"10.1016\/j.idc.2009.06.013_bib132","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2008.09.suppl52.280","article-title":"Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective","volume":"120","author":"Sahm","year":"2008","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib133","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.50.5.1855-1858.2006","article-title":"Streptococcus pneumoniae isolates resistant to telithromycin","volume":"50","author":"Rantala","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib134","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/mdr.2006.12.130","article-title":"Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan","volume":"12","author":"Lau","year":"2006","journal-title":"Microb Drug Resist"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1553-2712.2007.tb01844.x","article-title":"Community-acquired pneumonia in North American emergency departments: drug resistance and treatment success with clarithromycin","volume":"14","author":"Rowe","year":"2007","journal-title":"Acad Emerg Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib136","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2009.06.013_bib137","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib138","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007435-200209000-00001","article-title":"Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials","volume":"29","author":"Lau","year":"2002","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib139","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2007.04.015","article-title":"Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials","volume":"30","author":"Pitsouni","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"RR-11","key":"10.1016\/j.idc.2009.06.013_bib140","first-page":"1","article-title":"Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006","volume":"55","author":"Workowski","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib141","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0924-8579(03)00056-6","article-title":"Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis","volume":"21","author":"Skerk","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib142","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijantimicag.2004.03.014","article-title":"Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis","volume":"24","author":"Skerk","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib143","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007435-199403000-00010","article-title":"Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea: Azithromycin Gonorrhea Study Group","volume":"21","author":"Handsfield","year":"1994","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib144","first-page":"45","article-title":"Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease","volume":"31","author":"Bevan","year":"2003","journal-title":"J\u00a0Int Med Res"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jac\/dkn235","article-title":"Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland","volume":"62","author":"Palmer","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-147-2-200707170-00006","article-title":"Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance","volume":"147","author":"Wang","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib147","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1258\/ijsa.2007.007245","article-title":"Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials","volume":"19","author":"Bai","year":"2008","journal-title":"Int J STD AIDS"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib148","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMoa044284","article-title":"Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis","volume":"353","author":"Riedner","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2009.06.013_bib149","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"15","key":"10.1016\/j.idc.2009.06.013_bib150","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJMra020542","article-title":"Helicobacter pylori infection","volume":"347","author":"Suerbaum","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib151","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2003.01746.x","article-title":"Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication","volume":"18","author":"Vergara","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib152","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib153","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1365-2036.1999.00542.x","article-title":"Evaluation of treatment regimens to cure Helicobacter pylori infection: a meta-analysis","volume":"13","author":"Laheij","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib154","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1365-2036.2000.00744.x","article-title":"A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection","volume":"14","author":"Calvet","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib155","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1523-5378.2006.00459.x","article-title":"2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study","volume":"11","author":"Paoluzi","year":"2006","journal-title":"Helicobacter"},{"issue":"8","key":"10.1016\/j.idc.2009.06.013_bib156","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/0003-4819-146-8-200704170-00006","article-title":"Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial","volume":"146","author":"Vaira","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.idc.2009.06.013_bib157","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gut.2007.125658","article-title":"The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis","volume":"56","author":"Zullo","year":"2007","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib158","doi-asserted-by":"crossref","first-page":"923","DOI":"10.7326\/0003-4819-148-12-200806170-00226","article-title":"Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment","volume":"148","author":"Jafri","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib159","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7326\/0003-4819-136-1-200201010-00008","article-title":"Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993\u20131999","volume":"136","author":"Meyer","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1006.030744","article-title":"Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States","volume":"10","author":"Duck","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib161","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkm005","article-title":"Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy","volume":"59","author":"De Francesco","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib162","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/0003-4819-139-6-200309160-00008","article-title":"The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections","volume":"139","author":"McMahon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib163","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.49.4.1600-1603.2005","article-title":"Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib164","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1005457226341","article-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach","volume":"45","author":"Dore","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199608083350604","article-title":"Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both: California Collaborative Treatment Group","volume":"335","author":"Havlir","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib166","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/315380","volume":"181","author":"Benson","year":"2000","journal-title":"J Infect Dis"},{"issue":"RR-8","key":"10.1016\/j.idc.2009.06.013_bib167","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among HIV-infected persons\u20132002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America","volume":"51","author":"Kaplan","year":"2002","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib168","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1086\/520141","volume":"29","author":"Cohn","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib170","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","article-title":"A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib171","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1086\/317468","article-title":"A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus","volume":"31","author":"Dunne","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib172","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1086\/514999","article-title":"Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium","volume":"27","author":"Ward","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib173","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/ajrccm.149.5.8173775","article-title":"Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease","volume":"149","author":"Wallace","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib174","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","article-title":"Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/515597","article-title":"Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients","volume":"178","author":"Griffith","year":"1998","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib176","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1086\/313644","article-title":"Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex","volume":"30","author":"Griffith","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib177","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib178","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib179","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib180","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2009.06.013_bib181","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.013_bib182","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dkn250","article-title":"Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study","volume":"62","author":"Florescu","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib183","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijsu.2005.03.011","article-title":"Tigecycline is efficacious in the treatment of complicated intra-abdominal infections","volume":"3","author":"Fomin","year":"2005","journal-title":"Int J Surg"},{"key":"10.1016\/j.idc.2009.06.013_bib184","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2009.06.013_bib185","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib186","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2008.09.001","article-title":"Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin","volume":"63","author":"Bergallo","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib187","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2008.04.009","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia","volume":"61","author":"Tanaseanu","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib188","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/dkn311","article-title":"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies","volume":"62","author":"Kelesidis","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.013_bib189","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkn249","article-title":"A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae","volume":"62","author":"Vasilev","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib190","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1345\/aph.1L171","article-title":"Tigecycline for the treatment of Acinetobacter infections: a case series","volume":"42","author":"Gallagher","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.idc.2009.06.013_bib191","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1086\/379617","article-title":"Telithromycin and myasthenia gravis","volume":"37","author":"Nieman","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.013_bib192","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/526775","article-title":"Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline","volume":"46","author":"Anthony","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib193","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/0002-9343(91)90401-I","article-title":"Clinical toleration and safety of azithromycin","volume":"91","author":"Hopkins","year":"1991","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.idc.2009.06.013_bib194","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1345\/aph.18046","article-title":"Intravenous azithromycin","volume":"33","author":"Garey","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.idc.2009.06.013_bib195","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2165\/00002018-199308050-00003","article-title":"Overview of the tolerability profile of clarithromycin in preclinical and clinical trials","volume":"8","author":"Guay","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.idc.2009.06.013_bib196","unstructured":"Ketek (telithromycin) tablets: prescribing information. 2007;2008(November, 28)."},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib197","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mcp.2003.4","article-title":"Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects","volume":"73","author":"Demolis","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.idc.2009.06.013_bib198","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","article-title":"The FDA and the case of Ketek","volume":"356","author":"Ross","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib199","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-144-6-200503210-00121","article-title":"Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review","volume":"144","author":"Clay","year":"2006","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.idc.2009.06.013_bib200","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1212\/01.wnl.0000247741.72466.8c","article-title":"Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment","volume":"67","author":"Perrot","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.idc.2009.06.013_bib201","unstructured":"U.S. Food and Drug Administration. Telithromycin (marketed as Ketek) Information. 2007;2008(12\/22)."},{"issue":"3","key":"10.1016\/j.idc.2009.06.013_bib202","first-page":"1","article-title":"Acute pancreatitis related to tigecycline: case report and review of the literature","volume":"40","author":"Gilson","year":"2008","journal-title":"Scand J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.013_bib203","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0924-8579(01)00397-1","article-title":"Comparative safety of the different macrolides","volume":"18","author":"Rubinstein","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.idc.2009.06.013_bib204","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/106002809502900913","article-title":"Macrolides versus azalides: a drug interaction update","volume":"29","author":"Amsden","year":"1995","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.013_bib205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2125.2003.01824.x","article-title":"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction","volume":"56","author":"Rengelshausen","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.idc.2009.06.013_bib206","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1592\/phco.27.6.835","article-title":"Absence of an interaction between tigecycline and digoxin in healthy men","volume":"27","author":"Zimmerman","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.idc.2009.06.013_bib207","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1592\/phco.28.7.895","article-title":"Evaluation of a potential tigecycline-warfarin drug interaction","volume":"28","author":"Zimmerman","year":"2008","journal-title":"Pharmacotherapy"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552009000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:38:19Z","timestamp":1739425099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552009000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":207,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0891552009000592"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2009.06.013","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}